Acute graft versus host disease

This trial tests a combination of sirolimus, ruxolitinib, and mycophenolate mofetil to prevent acute graft-versus-host disease (aGVHD) in patients receiving a half-matched stem cell transplant. The study focuses on patients with blood cancers or severe aplastic anemia who cannot …

This pilot study tests whether a cream containing ruxolitinib, a drug that blocks certain immune signals, is safe and helpful for people who develop acute skin graft-versus-host disease (GVHD) after a stem cell transplant. Participants aged 2 to 35 with a malignancy and skin GVHD…

This early-phase trial tests whether adding vitamin C to standard steroid treatment helps people with gastrointestinal graft-versus-host disease (GVHD), a serious complication after a donor stem cell transplant. About 35 participants aged 5 and older will receive vitamin C plus s…

This study tests whether giving fecal microbiota (from a healthy donor) via a tube or scope into the gut can safely help children and young adults with severe intestinal graft-versus-host disease that hasn't improved with steroids. About 20 participants aged 3 months to 25 years …

This study tests whether giving the drug ruxolitinib early can prevent severe graft-versus-host disease (GvHD) in people getting a stem cell transplant. About 438 adults at intermediate-to-high risk, as identified by a special model called daGOAT, will be enrolled. The goal is to…

This early-phase trial tests a new treatment called CK0802 for people with severe graft-versus-host disease (GVHD) that does not respond to steroids. GVHD is a serious complication after a bone marrow or stem cell transplant, where donor immune cells attack the patient's body. CK…

This Phase 3 trial tests whether adding a stem cell therapy called remestemcel-L to the drug ruxolitinib can help adults with severe, steroid-resistant graft-versus-host disease (GVHD) after a bone marrow transplant. GVHD occurs when donor immune cells attack the patient's body. …

This study tests whether a new drug called gecacitinib, combined with standard anti-rejection medicine, can prevent a serious complication called graft-versus-host disease (GVHD) in people with myelofibrosis who receive a stem cell transplant. About 40 adults will take part. The …

This study tests a drug called ivarmacitinib to prevent acute graft-versus-host disease (aGVHD) in 32 people with blood cancers receiving a half-matched stem cell transplant. The goal is to see if the drug can lower the chance of severe GVHD and improve survival without long-term…

This study tests a new drug called gecacitinib for people with acute graft-versus-host disease (GVHD) after a stem cell transplant. It is for those who did not get better or could not tolerate the usual second-line treatment. The trial will include 15 adults and aims to see if th…

This early study tests whether probiotics made from the patient's own or their donor's gut bacteria can improve intestinal health in people with acute graft-versus-host disease (aGVHD) after a stem cell transplant. Ten participants over age 50 will take probiotic capsules and be …

This phase 2 trial tests a combination of Gecacitinib (a pill) and a corticosteroid as the first treatment for grade II to IV acute graft-versus-host disease (aGVHD), a serious complication after a stem cell transplant. The study will enroll 25 adults who have recently received a…